Rituximab: review and clinical applications focusing on non-Hodgkin’s lymphoma

References

• Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer 1 Clin. 51, 15–36 (2001).
   Google Scholar
• Horning SJ. Natural history of and therapy for the indolent non-Hodgkins lymphomas. Semin. Oncol 20, 75–88 (1993).
   PubMed Web of Science ®Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
   PubMed Web of Science ®Google Scholar
• Grossbard ML, Press OW Appelbaum FR, Bernstein ID, Nadler LM. Monoclonal antibody-based therapies of leukemia and lymphoma. B/ooc/80, 863–878 (1992).
   Google Scholar
• Weiner LM. Monoclonal antibody therapy of cancer. Semin. Oncol 26, 43–51 (1999).
   PubMed Web of Science ®Google Scholar
• Foon IKA. Monoclonal antibody therapies for lymphomas. Cancer' 6, 273–278 (2000).
   PubMed Web of Science ®Google Scholar
• Stashenko P, Nadler LM, Hardy R, Schlossman SE Characterization of a human B lymphocyte-specific antigen. J. Immunol 125, 1678–1685 (1980).
   PubMed Web of Science ®Google Scholar
• Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. B/ooc/63, 1424–1433 (1984).
   Google Scholar
• Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF, Stashenko P A unique cell surface antigen identifying lymphoid malignancies of B cell origin. I Clin. Invest. 67, 134–140 (1981).
   PubMed Web of Science ®Google Scholar
• Tedder TF, Engel P CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Tod. 15, 450–454 (1994).
   PubMedGoogle Scholar
• Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMI30 j7, 711–717 (1988).
   Google Scholar
• Nadler LM, Stashenko P, Hardy R eta]. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 40, 3147–3154 (1980).
   Google Scholar
• Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl. J. Med 306, 517–522 (1982).
   PubMed Web of Science ®Google Scholar
• Press OW, Appelbaum F, Ledbetter JA et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. B/ooc/69, 584–591 (1987).
   Google Scholar
• Colnaghi MI. Generation of monoclonal antibodies for in vivo approaches. int. J. Rad Appl. Instmm. B18, 15–18 (1991).
   PubMedGoogle Scholar
• LoBuglio AF, Wheeler RII, Trang J eta] Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl Acad. Sci. USA 86, 4220–4224 (1989).
   PubMed Web of Science ®Google Scholar
• Liu AY, Robinson RR, Murray ED, Jr., Ledbetter JA, Hellstrom I, Hellstrom KE. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J. 'almond 139, 3521–3526 (1987).
   Google Scholar
• Grillo-Lopez AJ. Rituximab: an insider's historical perspective. Semin. Oncol 27, 9–16 (2000).
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Bkoc/83, 435–445 (1994).
   Google Scholar
• Rituximab Package Insert: IDEC Pharmaceuticals Corporation and Genentech Inc. (2001).
   Google Scholar
• Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkins lymphoma: safety and efficacy of re-treatment. J. Clin. 0=1 18, 3135–3143 (2000).
   Google Scholar
• •This study demonstrates that patients who previously responded to rituximab can respond again to a second treatment with rituximab.
   Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Clin. Oncol 16, 2825–2833 (1998).
   Google Scholar
• ••A pivotal study that led to the approval ofrituximab by the FDA.
   Google Scholar
• Berinstein NL, Grillo-Lopez AJ, White CA et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol 9, 995–1001 (1998).
   Google Scholar
• •This study provides informative pharmacokinetics data on rituximab.
   Google Scholar
• National Cancer Institute sponsored study of classifications of non- Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkins Lymphoma Pathologic Classification Project. Cancer 49, 2112–2135 (1982).
   Google Scholar
• Maloney DG, Liles TM, Czerwinski DK et al.. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. B/ooc/ 84, 2457–2466 (1994).
   Google Scholar
• Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. IDEC-C2B8: results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol 15, 3266–3274 (1997).
   Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. B/ooc/90, 2188–2195 (1997).
   Google Scholar
• ••This study paved the way for the clinicaldevelopment of rituximab.
   Google Scholar
• Davis TA, White CA, Grillo-Lopez AJ et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a Phase II trial of rituximab. j Clin. 0=1 17, 1851–1857 (1999).
   Google Scholar
• •This study shows that even bulky >10 cm lymphoma masses can respond to rituximab therapy.
   Google Scholar
• Foran JM, Gupta RK, Cunningham D et al. AUK multicentre Phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. BE Haernatol. 109, 81–88 (2000).
   Google Scholar
• Piro LD, White CA, Grillo-Lopez AJ et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. °rico'. 10, 655–661 (1999).
   Google Scholar
• Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood 92, 1927–1932 (1998) .
   PubMed Web of Science ®Google Scholar
• •First study to show the activity of rituximab in patients with aggressive lymphoma.
   Google Scholar
• Foran JM, Rohatiner AZ, Cunningham D et al. European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma and small B-cell lymphocytic lymphoma. J. Clin. Oncol 18, 317–324 (2000).
   Google Scholar
• •The activity of rituximab is studied in a large number of patients with mantle cell lymphoma.
   Google Scholar
• Ghielmini M, Schmitz SF, Burki K et al. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann. 0=1 11, 123–126 (2000).
   Google Scholar
• Hainsworth JD, Burris HA, Morrissey LH eta]. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-hodgkin lymphoma. Blood 95, 3052–3056 (2000).
   Google Scholar
• Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. B/ooc/97, 101–106 (2001).
   Google Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. 17, 268–276 (1999).
   Google Scholar
• ••First combination study of rituximab withchemotherapy in patients with lymphoma.
   Google Scholar
• Grillo-Lopez A, Shen D, Lee D, Dallaire B, Dowden S, White CA. Rituximab: Sustained remissions in patients with relapsed or refractory low grade or follicular non-Hodgkin's lymphoma. Blood 96, 238b (2000).
   Google Scholar
• Czuczman M, Fallon A, Scarpace A et al. Phase II study of rituxan in combination with fludarabine in patients with low-grade or follicular B-cell lymphoma. Blood 96, 729a (2000).
   Google Scholar
• Cabanillas F, McLaughlin P, Hagemeister F et al. Molecular Responses with FND + Rituxan chemoimmunotherapy for stage IV indolent follicular non-Hodgkin's lymphoma. B/ooc/96, 331a (2000).
   Google Scholar
• Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J. Clin. Oncol 19, 389–397 (2001).
   PubMed Web of Science ®Google Scholar
• •First study of combining rituximab with CHOP in newly diagnosed patients with aggressive lymphoma.
   Google Scholar
• Howard OM, Gribben JG, Newberg D et aL Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma. B/ooc/94, 631a (1999).
   Google Scholar
• Romaguera J, Dang NH, Hagemeister F et al Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma. B/ooc/96, 733a (2000).
   Google Scholar
• Coiffier B, Lepage E, Herbrecht R et al. Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial. B/ooc/96, 223a (2000).
   Google Scholar
• ••The only study that demonstrated an improved survival over standard CHOP in patients with diffuse large cell lymphoma. This study was limited to elderly patients. A full report has not been published yet.
   Google Scholar
• Yang H, Rosove MET, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am. J. Hematol. 62, 247–250 (1999).
   Google Scholar
• Jensen M, Winkler U, ManzkeO, Diehl V, Engert A. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann. Hematol. 77, 89–91 (1998).
   Google Scholar
• Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J. Hematol. 66, 142–144 (2001).
   Google Scholar
• O'Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol 19, 2165–2170 (2001).
   PubMed Web of Science ®Google Scholar
• ••Activity of rituximab in CLL patients isdemonstrated.
   Google Scholar
• Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol 19, 2153–2164 (2001).
   PubMed Web of Science ®Google Scholar
• ••Activity of rituximab in CLL patients isdemonstrated.
   Google Scholar
• Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin. 0=1 27, 79–85 (2000).
   Google Scholar
• Byrd JC, White CA, Link B et al. Rituximab therapy in Waldenstrorris macroglobulinemia: preliminary evidence of clinical activity. Ann. °rico'. 10, 1525–1527 (1999).
   Google Scholar
• Zinzani PL, Ascani S, Piccaluga PP, Bendandi M, Pileri S, Tura S. Efficacy of rituximab in hairy cell leukemia treatment. Clin. Oncol. 18, 3875–3877 (2000).
   Google Scholar
• •Hairy cell leukemia cells express high levels of CD20 and respond to rituximab.
   Google Scholar
• Ruhstaller TVV, Amsler U, Cerny T Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann. Oncol 11, 374–375 (2000).
   Google Scholar
• Sabroe RA, Child FJ, Woolford AJ, Spittle MF, Russell-Jones R. Rituximab in cutaneous B-cell lymphoma: a report of two cases. BE J Dermatol 143,157–161 (2000).
   PubMed Web of Science ®Google Scholar
• Milpied N, Vasseur B, Parquet N et al Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann. Oncol 11, 113–116 (2000).
   Google Scholar
• Cook RC, Connors JM, Gascoyne RD, Fradet G, Levy RD. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet 354,1698–1699 (1999).
   Google Scholar
• Zompi S, Tulliez M, Conti F et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. Hepatol 32,521–527 (2000).
   Google Scholar
• Oertel SH, Anagnostopoulos I, Bechstein WO, Liehr H, Riess HB. Treatment of post-transplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation? Transplantation 69, 430–432 (2000).
   Google Scholar
• Kuehnle I, Huls MET, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. B/ooc/95,1502–1505 (2000).
   Google Scholar
• •One of several studies that demonstrated activity of rituximab in post-transplant lymphoproliferative diseases.
   Google Scholar
• Saleh MN, Gutheil J, Moore M et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin. Oncol 27,99–103 (2000).
   Google Scholar
• Zaja F, Russo D, Fuga G, Patriarca F, Ermacora A, Baccarani M. Rituximab for the treatment of Type II mixed cryoglobulinemia. .thematologica 84, 1157–1158 (1999).
   PubMed Web of Science ®Google Scholar
• Lim LC, Koh LP, Tan P Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia.j Gun. Oncol 17,1962-1963 (1999).
   Google Scholar
• Winkler U, Jensen M, ManzkeO, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). B/ooc/94,2217–2224 (1999).
   Google Scholar
• Sharma VR, Fleming DR, Slone SR Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 96, 1184–1186 (2000).
   PubMed Web of Science ®Google Scholar